Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SECAIII: Liver Transplantation vs Chemotherapy for CRC Liver Metastases
NCT03494946Recruiting
- Sponsor
- Oslo University Hospital
- Start
- Dec 2016
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Overall Survival at 2 years. Started Dec 2016; status: recruiting.
Beyond the preview
Go deeper on NCT03494946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03494946.